Kilitch Drugs Reports Strong Financial Growth Amid Rising Interest Costs in March 2025
Kilitch Drugs (India) has reported strong financial results for the quarter ending March 2025, with significant increases in profit before tax, profit after tax, and net sales. The company also achieved its highest operating profit and margin in five quarters, alongside improved earnings per share, despite rising interest costs.
Kilitch Drugs (India), a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a notable shift in the company's evaluation, with an adjustment in its score reflecting the positive developments observed during this period.The company achieved a profit before tax less other income (PBT) of Rs 12.14 crore, marking a significant growth compared to the average of the previous four quarters. Similarly, profit after tax (PAT) reached Rs 10.40 crore, showcasing a robust increase over the same comparative period. Net sales also reached a peak of Rs 61.23 crore, indicating a strong sales performance.
Operating profit and operating profit margin have also shown favorable trends, with the operating profit hitting Rs 14.60 crore and the margin at 23.84%, both representing the highest figures in the last five quarters. Additionally, earnings per share (EPS) reached Rs 6.47, reflecting enhanced profitability for shareholders.
However, it is worth noting that interest costs have risen, indicating increased borrowings. Overall, Kilitch Drugs has demonstrated a strong financial performance in this quarter, leading to a revision in its score.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
